| 英文名稱 | Danshensu |
|---|---|
| 中文名稱 | 丹參素/丹參酸甲/(R)-3-(3,4-二羥基苯基)-2-羥基丙酸/β-(3,4-二羥基苯基)乳酸 |
| CAS號 | 76822-21-4 |
| 分子式 | C9H10O5 |
| 分子量 | 198.17 |
| 外觀 | 白色粉末 |
| 沸點 | 481.5±40.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 3.82±0.10 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Danshensu |
|---|---|
| 中文名稱 | 丹參素/丹參酸甲/(R)-3-(3,4-二羥基苯基)-2-羥基丙酸/β-(3,4-二羥基苯基)乳酸 |
| CAS號 | 76822-21-4 |
| 分子式 | C9H10O5 |
| 分子量 | 198.17 |
| 外觀 | 白色粉末 |
| 沸點 | 481.5±40.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 3.82±0.10 | Condition: Most Acidic Temp: 25 °C |
| Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet | ||
| 來源：SCI：JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 作者：Dao-quan Tang | 備注：影響因子：2.983 |
| 引用描述 | ||
CBT was produced by Shenzhen Salubris Pharmaceuticals Co. Ltd. (Shenzhen, China), and FDDP was obtained from Tasly Pharmaceuticals Co. Ltd. (Tianjin, China). The reference compounds or internal standards danshensu, dihydrotanshinone I, tanshinone I, cryptotanshinone, tanshinone IIA and digoxin were purchased from Sichuan Weikeqi Biological Technology Co. Ltd. (Chengdu, China), and protocatechuic acid, ginsenoside Rb1, 3,4-dihydroxyphenylacetic acid, clopidogrel and phenanthrenequinone were from Aladdin Chemistry (Shanghai, China). | ||
| Pharmacokinetics and tissue distribution study of 15 ingredients of Polygonum chinense Linn extract in rats by UHPLC–MS/MS | ||
| 來源：SCI：BIOMEDICAL CHROMATOGRAPHY | 作者：Xiaoqing Chen | 備注：影響因子：1.728 |
| 引用描述 | ||
Thestandards of syringic acid, ferulic acid,p-coumaric acid, isoquercitrin,hyperoside, avicularin, quercitrin, and the IS of danshensu (IS2) werefrom Sichuan Weikeqi Biological Technology Co., Ltd. (Sichuan,China). The structure of analytes and ISs is presented in Figure 1.Acetonitrile, methanol, acetic acid, and formic acid of HPLC gradewere obtained from Thermo Fisher Scientific (Fair Lawn, NJ, USA) | ||
